Biopsy-Based Algorithm Found Accurate for Small Renal Masses

This article originally appeared here.
Share this content:
Biopsy-Based Algorithm Found Accurate for Small Renal Masses
Biopsy-Based Algorithm Found Accurate for Small Renal Masses

(HealthDay News) -- Compared with final pathology, biopsy of small renal masses (SRMs) can be accurately used in a treatment algorithm to direct management, according to research published in the February issue of The Journal of Urology.

Schuyler J. Halverson, M.D., of the University of Michigan Health System in Ann Arbor, and colleagues assessed the accuracy of a biopsy-directed treatment algorithm for correctly assigning 133 patients with SRMs (≤4 cm) to treatment or active surveillance.

Using a biopsy-directed treatment algorithm, 36 patients with SRMs were assigned to surveillance and 97 were treated. Based on the final pathology, the researchers found that 31 percent of those patients for whom surveillance was recommended should have received treatment, while no patients moved from treatment to surveillance. Seven of the 11 misclassified cases had a biopsy indicative of grade 1 clear cell renal cancer, which was upgraded to grade 2 or 3. Overall agreement between biopsy and final pathology was 92 percent; however, after adjustment of the algorithm to avoid undergrading of clear cell renal cancer, agreement improved to 97 percent, with negative and positive predictive values of 0.86 and 1.0, respectively.

"Image guided, percutaneous renal mass biopsy is highly accurate for diagnosis in most patients and provides valuable information to guide the management of SRM," the authors write. "We have shown that although slight discrepancies may exist between initial biopsy and final pathology due to the heterogeneous nature of some tumors, this variability becomes clinically irrelevant when using a well-defined management protocol."

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs